Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
伊布替尼联合利妥昔单抗治疗高危慢性淋巴细胞白血病患者的安全性和活性：一项单臂 2 期研究
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(14)70335-3
Burger Jan A, Keating Michael J, Wierda William G, Hartmann Elena, Hoellenriegel Julia, Rosin Nathalie Y, de Weerdt Iris, Jeyakumar Ghayathri, Ferrajoli Alessandra, Cardenas-Turanzas Marylou, Lerner Susan, Jorgensen Jeffrey L, Nogueras-González Graciela M, Zacharian Gracy, Huang Xuelin, Kantarjian Hagop, Garg Naveen, Rosenwald Andreas, O'Brien Susan
